Back to search
FDAFDA · Food and drugs·Recall number D-1785-2019

InFLIXimab 300 mg / 250 ml 0.9% NACL IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Published August 21, 2019 · Recall initiated: June 12, 2019

Summary

FDA records drug Class II recall D-1785-2019, published August 21, 2019 and initiated June 12, 2019. Recalling firm: Infusion Options, Inc.; Status: Terminated; Reported quantity: N/A; Lot: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Infusion Options, Inc.
Distributor
NY only
Lot
All lots within expiry
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was InFLIXimab 300 mg / 250 ml 0.9% NACL IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233 recalled?

Yes. FDA published recall D-1785-2019 on August 21, 2019. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter